What are the properties and uses of glutamine in clinical practice, particularly in relation to total parenteral nutrition, intestinal cellularity, essential amino acid status, and gluconeogenesis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Properties and Uses of Glutamine in Clinical Practice

Glutamine is a conditionally essential amino acid that serves as a substrate for gluconeogenesis, increases intestinal cellularity, and is commonly supplied in total parenteral nutrition for critically ill patients. 1

Glutamine's Role in Total Parenteral Nutrition (TPN)

  • Glutamine is the most abundant free amino acid in the body and has been increasingly incorporated into total parenteral nutrition formulations, particularly for critically ill patients 1
  • When PN is indicated in ICU patients, parenteral glutamine supplementation (0.2-0.4 g/kg/day of L-glutamine or 0.3-0.6 g/kg/day of alanyl-glutamine dipeptide) is recommended 1
  • Traditionally, L-glutamine was omitted from standard TPN formulations because crystalline L-glutamine is poorly soluble and degrades during heat sterilization, but glutamine-containing dipeptides (alanyl-glutamine or glycyl-glutamine) now provide stable and soluble alternatives 1
  • Clinical studies have shown that glutamine-supplemented TPN reduces infectious complications, shortens hospital length of stay, and improves glucose tolerance in critically ill patients 2

Effects on Intestinal Cellularity

  • Glutamine supplementation maintains intestinal structure and function, preventing intestinal atrophy associated with glutamine-free parenteral nutrition 3
  • Studies demonstrate that glutamine-enriched TPN maintains both B and T cell populations in the gut at levels similar to normal feeding, while standard TPN solutions lead to depletion of these immune cells 4
  • Glutamine serves as a primary energy substrate for rapidly dividing cells, particularly enterocytes, helping to maintain intestinal mucosal integrity 5
  • The addition of glutamine to TPN has been shown to increase intestinal cellularity and prevent increased intestinal permeability 3

Glutamine as a Conditionally Essential Amino Acid

  • Under normal conditions, glutamine is not an essential amino acid as it has an endogenous production rate (predominantly in skeletal muscle) of approximately 50-80 g/24h for an adult 1
  • However, during critical illness, glutamine becomes "conditionally essential" because the increased demand for its utilization (for immune function and tissue repair) exceeds the body's capacity to produce it 1
  • In critically ill patients, plasma glutamine levels often fall, and this hypoglutaminemia is associated with worse clinical outcomes 1
  • The body's inability to maintain adequate glutamine levels during severe stress states is why supplementation is often recommended 5

Role in Gluconeogenesis

  • Glutamine is a major substrate for gluconeogenesis, serving as a carrier for nitrogen and carbon between organs 1
  • It participates in protein and glucose metabolism and is involved in the regulation of ammonia and acid-base balance 1
  • During critical illness, there is increased dependence on glutamine as a gluconeogenic substrate due to increased protein catabolism and the inability of exogenous glucose to inhibit gluconeogenesis 1
  • This role in gluconeogenesis becomes particularly important in conditions like severe acute pancreatitis, where substrate metabolism is similar to that in severe sepsis or trauma 1

Clinical Applications and Recommendations

  • Glutamine supplementation is particularly beneficial in specific clinical scenarios:

    • Acute pancreatitis: When PN is indicated, parenteral glutamine supplementation (>0.30 g/kg Ala-Gln dipeptide) should be considered 1
    • Critically ill ICU patients: Glutamine supplementation has been associated with reduced mortality and improved morbidity with reduced infections 1
    • Surgical patients requiring exclusive PN: Parenteral glutamine supplementation may be considered, though evidence is less strong than for critical illness 1
  • Caution should be exercised with indiscriminate use of glutamine supplementation for all critically ill patients, as recent evidence suggests potential harm in certain subgroups 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.